QuickView for Mazindol (compound)

Summary
General Info

PubChem

PubChem Compound 4020

Name:	Mazindol
PubChem Compound ID:	4020
Description:	Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Molecular formula:	C₁₆H₁₃ClN₂O
Molecular weight:	284.74 g/mol
Synonyms:	3H-Imidazo(2,1-a)isoindol-5-ol, 2,5-dihydro-5-(4-chlorophenyl)-; AN 448; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; Dimagrir; Mazindolum [INN-Latin]; SA 42-548; Mazindol (JAN/USP); Mazildene; Magrilon. show more » 3H-Imidazo(2,1-a)isoindol-5-ol, 2,5-dihydro-5-(4-chlorophenyl)-; AN 448; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(p-chlorophenyl)-2,5-dihydro-; 3H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; Dimagrir; Mazindolum [INN-Latin]; SA 42-548; Mazindol (JAN/USP); Mazildene; Magrilon; 5-(p-Chlorophenyl)-2,5-dihydro-3H-imidazo(2,1-a)isoindol-5-ol; HSDB 3112; Mazindol; CCRIS 3152; S 42548; 5-24-04-00402 (Beilstein Handbook Reference); Mazindol [USAN:BAN:INN]; Teronac; BRN 0546547; EINECS 244-857-0; Sanorex (TN); 5-p-Chlorophenyl-2,3-dihydro-5H-imidazo(2,1-a)isoindol-5-ol; 3H-Imidazo[2,1-a]isoindol-5-ol, 5-(4-chlorophenyl)-2,5-dihydro-; DEA No. 1605; D00367; 5H-Imidazo(2,1-a)isoindol-5-ol, 5-(4-chlorophenyl)-2,3-dihydro; 22232-71-9; SAH 42548; Sanorex; Mazanor; 5-(4-Chlorophenyl)-2,3-dihydro-5-hydroxy-5H-imidazo(2,1-a)isoindole show less «

DrugBank

Identification

Name:	Mazindol
Name (isomeric):	DB00579
Drug Type:	small molecule
Description:	Tricyclic anorexigenic agent unrelated to and less toxic than AMPHETAMINE, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter.
Brand:	Mazanor, Mazindol [USAN:BAN:INN], Mazildene, Mazindolum [INN-Latin], Dimagrir, DEA No. 1605, Sanorex, Teronac, Terenac, Magrilon
Category:	Dopamine Uptake Inhibitors, Adrenergic Uptake Inhibitors, Central Nervous System Stimulants
CAS number:	22232-71-9

Pharmacology

Indication:	Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m<sup>2</sup>) or in patients with a body mass index of 27 kg/m<sup>2</sup> in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
Pharmacology:	Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to dec... show more » Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program. show less «
Mechanism of Action:	Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its relea... show more » Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release. show less «
Biotransformation:	Hepatic.
Half Life:	10-13 hours
Toxicity:	Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

May be taken without regard to meals, but preferably 1 hour before a meal.

If product causes GI problems, it can be taken during meals.

Drug interaction:

Mesoridazine	Decreased anorexic effect, may increase psychotic symptoms
Chlorpromazine	Decreased anorexic effect, may increase psychotic symptoms
Methdilazine	Decreased anorexic effect, may increase psychotic symptoms
Fluvoxamine	Risk of serotoninergic syndrome
Thiethylperazine	Decreased anorexic effect, may increase psychotic symptoms

Targets

Sodium-dependent noradrenaline transporter

Sodium-dependent dopamine transporter

Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals

UniProt ID:

Q01959

Gene:

SLC6A3

Actions:

inhibitor

References:

Itzhak Y, Martin JL: Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain Res. 1999 Feb 13;818(2):204-11.
View Article

Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A: Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6850-5.
View Article

Goettl VM, Wemlinger TA, Fong TG, Neff NH, Hadjiconstantinou M: Retinal cholinergic and dopaminergic deficits of aged rats are improved following treatment with GM1 ganglioside. Brain Res. 2000 Sep 15;877(1):1-6.
View Article

Tidjane Corera A, Do-Rego JC, Costentin J, Bonnet JJ: Differential sensitivity to NaCl for inhibitors and substrates that recognize mutually exclusive binding sites on the neuronal transporter of dopamine in rat striatal membranes. Neurosci Res. 2001 Mar;39(3):319-25.
View Article

Purkerson-Parker S, McDaniel KL, Moser VC: Dopamine transporter binding in the rat striatum is increased by gestational, perinatal, and adolescent exposure to heptachlor. Toxicol Sci. 2001 Dec;64(2):216-23.
View Article

Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58.
View Article

Kulkarni SS, Newman AH, Houlihan WJ: Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4119-27.
View Article

Houlihan WJ, Kelly L, Pankuch J, Koletar J, Brand L, Janowsky A, Kopajtic TA: Mazindol analogues as potential inhibitors of the cocaine binding site at the dopamine transporter. J Med Chem. 2002 Sep 12;45(19):4097-109.
View Article

Sodium-dependent serotonin transporter